Literature DB >> 12405290

Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.

Hiroyuki Konno1, Megumi Baba, Tuyoshi Shoji, Manabu Ohta, Shohati Suzuki, Satoshi Nakamura.   

Abstract

Considering recent findings that cyclooxygensase-2 (COX-2) is involved in the progression of colorectal carcinoma (CRC), the role of COX-2 in promoting invasion and angiogenesis was investigated by evaluating the relationship of COX-2 expression to various clinicopathological variables, including plasminogen activating system (PA system) and vascular endothelial growth factor (VEGF). Tumor tissues from 71 patients with CRC were assayed to determine the antigen levels of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 and -2 (PAI-1 and PAI-2), as well as immunohistochemical expression of VEGF. COX-2 was assayed immunohistochemically in 56 patients. COX-2 expression was detected in cancer cells and it was also expressed by stromal cells in some patients. Fourteen patients (25%) were COX-2 positive, whereas 42 were negative. COX-2 expression was significantly related to lymphatic invasion (P = 0.0317), but was not related to microvessel density or VEGF expression. In the PA system, uPAR antigen levels were significantly higher in tumors with COX-2 expression than in tumors without (P = 0.0233). Univariate analysis showed that significant prognostic variables for survival were tumor size, lymph node involvement, lymphatic invasion, vascular invasion, liver metastasis, high uPAR level, and COX-2 expression, but only liver metastasis was an independent prognostic factor (P = 0.0065) in multivariate analysis. COX-2 expression was a more important prognostic indicator than any other factor except liver metastasis (P = 0.0526). The significant relationship between the presence of COX-2 protein and uPAR antigen levels contributed to the enhancement of tumor invasion and the poor outcome in patients with CRC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12405290     DOI: 10.1023/a:1020392309715

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  50 in total

1.  Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.

Authors:  M Dohadwala; J Luo; L Zhu; Y Lin; G J Dougherty; S Sharma; M Huang; M Pold; R K Batra; S M Dubinett
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

2.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

3.  Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells.

Authors:  M R Pan; L Y Chuang; W C Hung
Journal:  FEBS Lett       Date:  2001-11-23       Impact factor: 4.124

Review 4.  Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.

Authors:  J S Rao; P A Steck; P Tofilon; D Boyd; F Ali-Osman; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.

Authors:  N P McCabe; F F Angwafo; A Zaher; S H Selman; A Kouinche; J Jankun
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

6.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

7.  Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator.

Authors:  J Keski-Oja; J Lohi; A Tuuttila; K Tryggvason; T Vartio
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

8.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

Authors:  D J Elder; D E Halton; A Hague; C Paraskeva
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

9.  A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.

Authors:  G Nishimura; S Yanoma; H Mizuno; K Kawakami; M Tsukuda
Journal:  Jpn J Cancer Res       Date:  1999-10

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  13 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

2.  Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.

Authors:  Gabriel Scicolone; Viviana Sanchez; Liliana Vauthay; Federico Fuentes; Alejandro Scicolone; Lorenzo Scicolone; Melina Rapacioli; Vladimir Flores
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

3.  Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.

Authors:  Li Zhang; Zhong-Sheng Zhao; Guo-Qing Ru; Jie Ma
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

4.  Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.

Authors:  Terence-C Tang; Ronnie-T Poon; Cecilia-P Lau; Dan Xie; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

5.  Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.

Authors:  Hongxia Li; Qinyue Guo; Bo Zhou; Shuixiang He
Journal:  Oncol Lett       Date:  2015-07-09       Impact factor: 2.967

Review 6.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

7.  Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

Authors:  Douglas M Evans; Kimberly D Sloan Stakleff
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

8.  Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Authors:  Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

9.  The role of COX-2 in rectal cancer treated with preoperative radiotherapy.

Authors:  Hanifa Bouzourene; Pu Yan; Dominique Sandmeier; Abderrahim Zouhair; Maurice Matter; Henri Vuilleumier; Philippe Coucke
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

10.  Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.

Authors:  Peter P Grimminger; Jan Stöhlmacher; Daniel Vallböhmer; Paul M Schneider; Arnulf H Hölscher; Ralf Metzger; Peter V Danenberg; Jan Brabender
Journal:  J Oncol       Date:  2009-11-22       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.